利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.025 秒)

    Azithromycin dosage forms with reduced side effects
    4.
    发明申请
    Azithromycin dosage forms with reduced side effects 有权
    阿奇霉素剂型具有减少的副作用

    公开(公告)号：US20050123627A1

    公开(公告)日：2005-06-09

    申请号：US10763340

    申请日：2004-01-23

    申请人： Timothy Hagen ,  Julian Lo ,  Avinash Thombre ,  Scott Herbig ,  Leah Appel ,  Marshall Crew ,  Dwayne Friesen ,  David Lyon ,  Scott McCray ,  James West

    发明人： Timothy Hagen ,  Julian Lo ,  Avinash Thombre ,  Scott Herbig ,  Leah Appel ,  Marshall Crew ,  Dwayne Friesen ,  David Lyon ,  Scott McCray ,  James West

    IPC分类号： C07H17/00 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/7052 ,  A61K47/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/44 ,  A61P31/04 ,  A01N59/26 ,  A61K31/198 ,  A61K31/7008 ,  A61K33/10 ,  A61K33/42

    CPC分类号： A61K9/1611 ,  A61K9/143 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1694 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2031 ,  A61K31/7052

    摘要： An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.

    摘要翻译： 包含阿奇霉素和有效量的碱化剂的口服剂型。 优选地，所述口服剂型包含有效量的碱化剂和阿奇霉素多颗粒，其中所述多颗粒包括阿奇霉素，单山嵛酸甘油酯，二苯乙酸甘油酯和枸橼酸甘油酯和泊洛沙姆的混合物。 通常，口服剂型包括任何合适的口服给药方式，例如用于口服悬浮液的粉末，单位剂量包或小药囊，片剂或胶囊。 另外公开了包含阿奇霉素，有效量的碱化剂和载体的口服悬浮液。 优选地，阿奇霉素是多颗粒形式，其中所述多颗粒包括阿奇霉素，甘油单山嵛酸甘油酯，二苯甲酸甘油酯和枸橼酸甘油酯和泊洛沙姆的混合物。 还公开了一种减少与向哺乳动物施用阿奇霉素相关的胃肠道副作用的方法，包括向所述哺乳动物连续施用阿奇霉素和有效量的碱化剂，其中胃肠道副作用的频率低于施用相等剂量 的阿奇霉素不含碱化剂。 进一步公开的是一种在有需要的哺乳动物中治疗细菌或原生动物感染的方法，其包括向所述哺乳动物连续施用单剂量的口服剂型，其中所述口服剂型包含阿奇霉素和有效量的碱化剂。 另外公开了包含阿奇霉素，表面活性剂的阿奇霉素多颗粒; 和药学上可接受的载体。

    Hydrogel-Driven Drug Dosage Form
    7.
    发明申请
    Hydrogel-Driven Drug Dosage Form 审中-公开
    水凝胶驱动的药物剂型

    公开(公告)号：US20070087057A1

    公开(公告)日：2007-04-19

    申请号：US11610603

    申请日：2006-12-14

    申请人： Leah Appel ,  Ronald Beyerinck ,  Mark Chidlaw ,  William Curatolo ,  Dwayne Friesen ,  Kelly Smith ,  Avinash Thombre

    发明人： Leah Appel ,  Ronald Beyerinck ,  Mark Chidlaw ,  William Curatolo ,  Dwayne Friesen ,  Kelly Smith ,  Avinash Thombre

    IPC分类号： A61K9/24

    CPC分类号： A61K9/0004

    摘要： A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The drug-containing composition comprises a low-solubility drug and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed.

    摘要翻译： 控释剂型具有涂覆的核心，其核心包含含药物的组合物和水溶胀性组合物，每个组合物占据核心内的分开的区域。 含药组合物包含低溶解度药物和药物引诱剂。 芯周围的涂层是透水的，不溶于水的，并且具有至少一个通过其的输送口。 公开了具有特定药物释放曲线的多种制剂。